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WHAT'sb IN IT FOR
It's a classic battle cry. Researchers have
long argued, even pleaded, for the U.S.
government to fund public health pro-
grams in developing countries. In the past
few years, U.S. spending on aid to foreign
countries has slipped behind that ofJapan,
France, and Germany, with only scattered
agencies supporting pet projects. Some
economists suggest that U.S. aid has lev-
eled offand could stay stagnant foryears to
come. Meanwhile, the world continues to
shrink; travelers cross the globe in hours,
companies set up shop in foreign countries,
and infectious viruses and drug-resistant
bacteria creep across national borders. And
as the world's population ages, skyrocket-
ing chronic disease douds the horizon.
So it's with growing urgency that
health researchers sound a new wake-up
call. Rather than appeal to altruism, scien-
tists and analysts are now focusing on the
bottom line: U.S. health and dollars. A
new report, America's Vital Interest in
Global Health, released in June by the
Institute of Medicine's (IOM) Board on
International Health, details how U.S.
research and business would benefit from
a unified global health program. The
report, available on the Internet at URL
http://www.nap.edu/readingroom/books/
avi, argues that we can't afford to ignore
our neighbors' problems. Instead, we
should apply science and technology solu-
tions, and reap the rewards.
"Okay, so we can't solve all the poverty
and environment problems of the world,"
says report co-chairperson Barry Bloom, a
Howard Hughes Medical Institute investi-
gator and an immunologist at Albert
Einstein College ofMedicine in NewYork.
"[But] health, we know how to do an
awful lot about. We could be the world
leader in health. And it's cost-effective."
Bloom and colleagues offer concrete rec-
ommendations for getting the United States
more involved in global health. The IOM
report calls for more research and education
about diseases of the developing world, a
global surveillance system to spot environ-
mental changes and emerging disease con-
ditions, public and private sector partner-
ships to distribute vaccines and drugs over-
seas, and a new government body, the
Interagency Task Force on Global Health,
to help coordinate these efforts.
Researchers welcome the report. "I'm
pleased that they focused on the policy
implications for the U.S.," says Burton
Kross, director of the Center for
International Rural and Environmental
Health at the University of Iowa in Iowa
City. "They're not just laying out the
problems. Instead, they're providing a
framework for what the U.S. should do."
It's still unclear how dosely Congress and
government agencies will follow that
framework, which is intended to help
politicians and granting agencies better
understand global health issues. But the
report's authors are optimistic. "There's a
lot we could do that's not extravagant,"
Bloom says. "All it takes is leadership."
Emerging Crisis and Opportunity
Over the past few years, the concept of a
"global village," a world where everyone's
lives are intertwined via travel and busi-
ness, has taken shape. Similarly, researchers
now propose a model for global, not just
international, health. Their point is that
Nebraska and New Delhi are closer than
one might think-and getting closer. For
example, a company may have headquar-
ters, and thus a vested interest, in both
places. Suddenly, scientists argue, "their"
problems become "ours."
And problems there are. The health
story of the decade is emerging disease,
pathogens that creep seemingly from
nowhere to cause widespread illness. In
Latin American countries, it's cholera. In
Kenya, yellow fever. In Costa Rica, dengue
fever. And the list goes on-malaria, AIDS,
Ebola fever, tuberculosis. These disease epi-
demics stem from changes in the environ-
ment, such as heavy rains or hot tempera-
tures, and human behavior, particularly
increased urbanization, which often leads to
crowded, unsanitarylivingconditions.
Drug resistance is another global health
problem. In a handful ofcountries, rough-
ly half the infections caused by certain
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streptococcus, staphylococcus, and mycobac-
terium strains ofbacteria are drug resistant.
In the United States alone, the total cost to
treat one case ofdrug-resistant tuberculosis
is $250,000, compared to the $25,000
normally needed to fight one incidence of
thedisease.
And there are more clouds on the
horizon. Much like the United States, the
developing world is in a demographic
transition; people are getting older.
Demographers estimate that over the next
30 years, the number of adults ages 45
and older in the developing world will
double, while the number ofchildren will
rise by just 20%. The shift translates into
more people developing chronic condi-
tions prevalent in older adults, induding
heart disease, depression, lung disease,
and brain disorders such as Alzheimer's
and Parkinson's diseases.
"The pattern of disease is, and will
continue, becoming much more similar
between middle-income countries in the
Middle East, Latin America, Asia, and the
United States," says Christopher Murray,
an international health researcher at
Harvard University. "A bigproblem is that
ifyou're a lower-middle income country,
there's not a lot ofresearch [happening] on
cost-effective strategies for dealing with
noncommunicable diseases."
In combination, emerging diseases,
drug resistance, and rising rates ofchronic
conditions deliver a whopping public
health challenge to the developing world,
which presents unprecedented health
research opportunities for the United
States, says Murray. For example, the
worldwide increase in age-related diseases
means research conducted overseas can be
directly applied to health care at home.
"The potential to learn from what's done
in the Netherlands or Chile is greater than
everbefore," Murraysays.
Seizing this fact, the IOM report urges
the government to fund dinical trials and
chronic disease research in developing coun-
tries. Similarly, it lobbies for more collabo-
ration between international scientists and
education for health specialists in other
countries. "As the burden ofdisease in the
developing world shifts from acute infec-
tious disease to more chronic disease, we
have a great need for highly trained health
professionals in those areas," says Philip
E. Schambra, director of the Fogarty
Intemational Center in Bethesda, Maryland.
"Thereare many, manygaps."
In fact, great gaps still exist in control-
ling emerging disease. For more than five
years, public health specialists have pressed
the government to start a global surveil-
lance system that tracks environmental and
disease conditions worldwide. The idea is
to spot disease outbreaks early, responding
before infection spirals out of control.
"Eventually, we might find environmental
markers such as climate change that sug-
gest what kinds ofproblems may come,"
says Stephen Morse, director of the pro-
gram in emerging diseases at Columbia
University in NewYork.
While some strides have been made-
forexample, theWorld Health Organization
(WHO), the CDC, and otherorganizations
have bolstered emerging disease efforts-a
comprehensive global surveillance system
does not exist. The IOM report emphasizes
the need for such a system because, by pro-
tectingpopulations overseas, researchers also
would safeguard health at home. In the
United States, for example, where outbreaks
ofLymedisease, hantavirus, E. colicontami-
nation, andAIDS all threaten public health,
answers aredesperatelyneeded.
Another way to fight infectious disease
is to deliver vaccines and drugs to develop-
ing countries. Today, few U.S. companies
develop vaccines for overseas markets
because there's little chance for profit. The
IOM report supports a multi-tiered pricing
scheme in which companies offer vaccines
cheaply to developing countries. In the
past, politicians have lambasted such pric-
ing schemes as unfair to U.S. citizens, who
would pay more for the same medicine. In
addition, the IOM report calls on the gov-
ernment to safeguard intellectual property
rights, extend patents, and basically sup-
port the efforts of drug companies selling
products overseas.
These strategies would pay offby both
saving money and protecting U.S. health,
researchers say. "Take smallpox," says
Gerald Poje, director of international pro-
grams and public health at the NIEHS.
"Eradicating that disease has saved the U.S.
billions ofdollars in prevention and treat-
ment costs." But it's not enough, Poje says,
to vaccinate U.S. children against diseases.
"It's currently estimated that nobody is
more than a day and a halfaway from any-
place in the world," he says. Therefore, to
protect their populations, countries must
venture beyond their own borders.
The Locus Issue
Unfortunately, IOM panel members say,
the United States is poorly prepared to
examine health issues beyond its borders.
The report takes aim at what Christopher
Howson, director of the Board on
International Health, calls "the locus
issue"-the absence of a single U.S. gov-
ernment body coordinating global health
efforts. Right now, the United States
Agency for International Development
(USAID), the NIH, the CDC, and the
Department of Defense (DOD) all fund
some global health research or programs.
In addition, the Department ofHealth and
Human Services (DHHS) also represents
the United States in development efforts
organized by the WHO. A host ofprivate
organizations, like the MacArthur, Pew,
and Rockefeller foundations, support glob-
al health projects as well.
"The whole issue ofglobal health is too
complex to be dealt with by any one
agency," Howson says. "What we're argu-
ing is that there needs to be a locus of
coordination to help leverage scarce human
and financial resources in the interest of
global health. Right now, that locus does
not exist."
Also missing, IOM report authors say,
is a financial commitment by the United
States. In 1995, the country spent about
0.1% ofits gross national product (GNP),
or about $7 billion, on foreign aid, the
lowest percentage among industrialized
countries. By comparison, the United
Kingdom and France spent about 0.29%
and 0.56% of their GNP, respectively.
Bloom and others also note that the United
States has fallen billions of dollars behind
in aid-related payments to the United
Nations and the WHO. At press time,
President Clinton had asked Congress for
$1 billion to help paythesedebts.
Ironically, the reality of foreign aid
sharply contrasts with public perception.
Several nationwide surveys suggest that
U.S. citizens support far higher investment
in global health and international develop-
ment. In a 1995 poll conducted by the
program on international policy attitudes
at the University of Maryland, for exam-
ple, those surveyed said the United States
should spend about 15% of the federal
budget on foreign aid, an amount 150
times greater than thatactuallyspent.
"The polls indicate that most people
favor helping developing countries with
health issues," says David Rall, a report
contributor who is also the IOM foreign
secretary and director emeritus of the
NIEHS. "In fact, the average person vasdy
overestimates how much moneywe do give
away." Americans also might be surprised
at how much can be accomplished with
minimal taxpayer dollars, he adds.
To improve the U.S. global health
effort, the IOM report proposes creating
the Interagency Task Force on Global
Healthwithin thegovernment. Representing
agencies such as the USAID, the CDC,
the DOD, and the Food and Drug
Administration, the task force would be a
strategic leader, coordinating global health
projects and recruiting partnerships with
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academia, industry, and international
agencies. The report recommends giving
the DHHS earmarked funds and specific
authority to create the new task force.
But can disparate agencies, amid bud-
get-conscious times, really share their turf
in such a coordinated fashion to meet a
common goal? Linda Vogel, deputy direc-
tor ofthe DHHS, isn't sure. "I'm not con-
vinced that having an interagency commit-
tee is the best way to deal with global
health problems," Vogel says. "A commit-
tee cannot necessarily overcome resistance
by one agency or another to following their
own vision ofwhat needs to be done." For
example, she notes, the DHHS might put
a different twist on problems of child sur-
vival than the USAID does. Which view-
point becomes the standard?
Vogel also stresses the complexity of
global health problems. In the developing
world, just getting vaccines transferred
from the hands of the government into
needy communities can be challenging. "In
almost every country, there's the same
question: how do you get resources to the
periphery?" Vogel says. "And how do you
provide appropriate regulatory oversight?
What's more, how do you teach people
about their personal responsibility for their
own health? You've got to deal with super-
stitions, myths, traditional practices."
Still, researchers say that with a little
work they can bridge the borders separating
both government agencies and geographic
regions. At the University of Iowa, for
example, Kross collaborates with researchers
from the Medical Center for Health
Services and Management in Timisoara,
Romania. Together, the team is studying
Romanian children who were exposed to
nitrates and developed methemoglobinemia
("blue baby disorder"), which can lead to
developmental defects as children age. Over
the past five years, an estimated 500 infants
in a small Romanian region developed the
disorder. These and other projects have
been funded by private and public organi-
zations, including the NIH, the USAID,
the EPA, and the company Pioneer Hi-
Bred International, headquartered in Des
Moines, Iowa.
"These are the kinds of partnerships
and research collaborations that the IOM
report has in mind," says Kross. "I think
people need to quit debating the feasibility
and get on with it." Rall agrees. "It's hard
to predict what will come from this
report," he says, "but we've got to get glob-
al health issues on the table. The more we
get people talking, the better offwe are."
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American Society of Tropical Medicine and Hygiene
Now available:
Directory of Clinical Consultants in Tropical Medicine and Travelers' Health
The 1997 edition of the Clinical Consultants Directory has just been issued by the American
Society of Tropical Medicine and Hygiene.
The publication contains a list of physicians who offer clinical consultative service in tropical
medicine, medical parasitology, and travelers' health. Details on office hours and services
provided by physicians are included in the directory.
The directory is maintained and updated by the American Committee on Clinical Tropical
Medicine and Travelers' Health (ACCTMTH), a subgroup of ASTMH. The purpose of ACCTMTH is
to promote the clinical aspects of tropical medicine, medical parasitology, and travelers' health.
To order a copy of the directory, send a self-addressed 9x12 envelope with $1.24 postage to:
ASTMH Clinical Directory, 60 Revere Drive, Suite 500, Northbrook, IL 60062 USA.
The directory can also be accessed through the ASTMH home page at http://www.astmh.org
Founded in 1951, ASTMH currently boasts over 3,000 members from more than 70 countries. ASTMH is the principal organization
representing scientists, clinicians, and others with interests in the prevention and control of tropical diseases.
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